16.59
price down icon6.38%   -1.051
 
loading
Schlusskurs vom Vortag:
$17.64
Offen:
$17.54
24-Stunden-Volumen:
59,417
Relative Volume:
0.43
Marktkapitalisierung:
$722.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.20%
1M Leistung:
+59.86%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$16.11
$18.40
1-Wochen-Bereich:
Value
$15.17
$18.67
52-Wochen-Spanne:
Value
$6.71
$18.67

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name
Firmenname
Maze Therapeutics Inc
Name
Telefon
(650) 850-5070
Name
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Name
Mitarbeiter
125
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
MAZE's Discussions on Twitter

Vergleichen Sie MAZE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MAZE
Maze Therapeutics Inc
16.50 741.92M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.92 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.46 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-08 Eingeleitet Wedbush Outperform

Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten

pulisher
Jul 23, 2025

Maze Therapeutics Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Maze Therapeutics Inc. stock priceExceptional market positioning - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating - Investing.com UK

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Maze Therapeutics Inc. stockExceptional growth trajectory - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Is Maze Therapeutics Inc. a good long term investmentHigh-velocity gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

What makes Maze Therapeutics Inc. stock price move sharplySecure Your Capital Strategy - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Why Maze Therapeutics Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser

Jul 22, 2025
pulisher
Jul 19, 2025

how maze therapeutics inc. stock performs during market volatilityDaily Trade Opportunity - Newser

Jul 19, 2025
pulisher
Jul 15, 2025

How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at Wedbush - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Q2 Earnings Estimate for Maze Therapeutics Issued By Wedbush - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $23.50 - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Maze Therapeutics Showcases Precision Medicine Pipeline at Major Kidney and Biotech Investor Conferences - Stock Titan

Jul 10, 2025
pulisher
Jul 10, 2025

Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest

Jul 10, 2025
pulisher
Jul 08, 2025

Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says - MarketScreener

Jul 08, 2025
pulisher
May 29, 2025

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire

May 29, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 21, 2025

Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail

May 21, 2025
pulisher
May 19, 2025

Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position - TipRanks

May 19, 2025
pulisher
May 18, 2025

Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World

May 18, 2025
pulisher
May 16, 2025

Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World

May 16, 2025
pulisher
May 14, 2025

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Maze Therapeutics Q1 Earnings: Dual Clinical Programs Progress as Cash Position Hits $294M - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Maze Therapeutics CEO to Present Company Overview at 3rd Annual H.C. Wainwright BioConnect Investor Conference - Nasdaq

May 13, 2025

Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)

Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$113.95
price down icon 0.57%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):